MedTrace Logo

Latino Semaglutide Study

NCT05087342 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2024-10-15

No results posted yet for this study

Summary

The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.

Conditions

  • Obesity
  • Obesity; Drug
  • Overweight or Obesity
  • Weight Loss
  • Weight Loss Trajectory
  • Weight, Body

Interventions

DRUG

Semaglutide 2.4mg

The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.

DRUG

Placebo

A placebo will be given to the control group per the schedule outlined in the armed description.

Sponsors & Collaborators

Principal Investigators

  • Warren Peters, MD · Loma Linda University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-13
Primary Completion
2024-05-29
Completion
2024-05-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05087342 on ClinicalTrials.gov